Behind BD’s Recent New Stock Price High



BD’s stock performance

Becton, Dickinson, and Company (BDX), or BD, closed trading at $195.3 on July 6, 2017, ahead of its 50-day moving average of $191.3 and its 200-day moving average of $181.9.

On July 6, 2017, BDX stock was trading ~21% above its 52-week low of $161.29 on December 7, 2016. It was trading ~0.69% below its 52-week high of $196.66 on the same day. Since BD’s fiscal 2Q17 earnings release on May 2, 2017, the company’s stock price has gained ~4.8%. On earnings day, the stock price fell ~0.6%.

On April 23, 2017, BD’s stock price fell ~4%, triggered by its announcement of the acquisition of C.R. Bard.

But BD stock has returned ~18% on YTD (year-to-date) basis, and the stock has been growing over the past few months on the back of positive investor sentiment.

Article continues below advertisement

Peer stock performances

As of July 7, 2017, peers Boston Scientific (BSX), Abbott Laboratories (ABT), and Stryker (SYK) have returned ~15%, ~18%, and ~21%, respectively, over the past year.

BDX stock has gained ~15% in the past year. The stock has marginally outperformed the S&P 500 Index, which has returned ~14.6% over the same period.

BD’s stock performance can also be compared to the performance of the iShares US Medical Devices ETF (IHI), which represents the US medical device sector. IHI has returned ~21% over the past year.


More From Market Realist